Anti-CD33 Antibodies Modulate Immune Response for Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CD33 antibodies primarily target leukemia cells but lack efficacy in treating solid tumor cells and do not effectively downregulate CD33 activity in conditions like Alzheimer's disease or enhance anti-tumor immune responses in cells that do not express CD33.
Innovation Solution
Development of human anti-CD33 antibodies that can decrease cell surface levels of CD33 or inhibit CD33 ligand binding, or a combination of both, to modulate immune cell functions and tumor responses, including the use of monoclonal antibodies, soluble CD33 receptors, and other agents to target CD33-expressing cells and tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-CD33 antibodies are used to target leukemia cells, then leukemia cell targeting is improved, but efficacy in treating solid tumor cells and downregulation of CD33 activity in Alzheimer's disease is insufficient
Solution Approach 1:
The patent develops anti-CD33 antibodies with multiple functions: they can target CD33-expressing leukemia cells, solid tumor cells, and modulate immune cell functions. The antibodies achieve both direct tumor cell targeting and indirect immune modulation effects, making them versatile across different disease types including leukemia, solid tumors, and neurodegenerative conditions.
Solution Approach 2:
The patent utilizes CD33 as an intermediary target that connects different therapeutic mechanisms. By targeting CD33 on various cell types (tumor cells and immune cells), the antibodies mediate both direct anti-tumor effects and indirect immune system modulation, bridging the gap between direct targeting and immune-based therapies.
2Reliability
If anti-CD33 antibodies bind to CD33 on tumor cells, then tumor cell targeting is improved, but enhancement of anti-tumor immune responses in CD33-negative cells is limited
Solution Approach 1:
The antibodies use CD33-expressing cells as intermediaries to activate immune responses that can then act on CD33-negative tumor cells. The immune system is stimulated through CD33-targeting to produce effector cells and cytokines that can attack broader tumor populations regardless of CD33 expression.
Solution Approach 2:
The therapeutic effect is segmented into two components: direct targeting of CD33-positive cells and indirect immune-mediated targeting of CD33-negative cells. This segmentation allows the treatment to address both CD33-expressing and non-expressing tumor populations through different mechanisms.
3Measurement precision
If anti-CD33 antibodies are designed for high specificity to CD33, then specificity is improved, but ability to modulate immune cell functions is reduced
Solution Approach 1:
The antibodies maintain high specificity for the CD33 antigen while achieving multiple functional outcomes: direct tumor cell binding, immune cell modulation, and cytokine induction. The single antibody molecule performs multiple roles through its specific CD33 binding, affecting both tumor cells and immune cells that express or interact with CD33.
Data Source
AI summary
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.